about
Antimicrobial stewardship in residential aged care facilities: need and readiness assessment.Patterns of use and appropriateness of antibiotics prescribed to patients receiving haemodialysis: an observational studyCase-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia.Penetration of topically administered 0.5-percent caspofungin eye drops into human aqueous humorPharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey.Community-onset bloodstream infection with multidrug-resistant organisms: a matched case-control studyCharacterising the Transmission Dynamics of Acinetobacter baumannii in Intensive Care Units Using Hidden Markov ModelsStability of extemporaneously prepared 0.5-percent caspofungin eye drops: a potential cost-savings exerciseRelationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.Modeling the impact of interventions against Acinetobacter baumannii transmission in intensive care units.Open-Label Study of Absorption and Clearance of 1% Voriconazole Eye Drops.Reducing inappropriate antibiotic prescribing in the residential care setting: current perspectives.The pharmacoeconomics of managing acute agitation in the emergency department: what do we know and how do we approach it?Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis.Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives.The cost-effectiveness of boceprevir for hepatitis C.Clinical utility of caspofungin eye drops in fungal keratitis.Optimizing hospital infection control: the role of mathematical modeling.Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.Management of acute agitation in Hong Kong and comparisons with Australasia.Patient expectations and willingness to use primary care pharmacy services in the United Arab Emirates.Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia.Factors influencing the cost of prosthetic joint infection treatment.Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey.Antibiotics in surgical wards: use or misuse? A newly industrialized country's perspective.Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience.Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.Impact of vanB vancomycin-resistant enterococcal bacteraemia analysed as a time-varying covariate on length of hospital stay.Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia.Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies.Community pharmacy in the United Arab Emirates: characteristics and workforce issues.Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients.Preemptive treatment with voriconazole in lung transplant recipients.Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.Investigation of structure-activity relationships in a series of glibenclamide analogues.Surveillance of infection burden in residential aged care facilities.Development and validation of the Beliefs and Behaviour Questionnaire (BBQ).Treatment of Alternaria keratitis with intrastromal and topical caspofungin in combination with intrastromal, topical, and oral voriconazole.Economic evaluation of micafungin vs. Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC)
P50
Q30585570-BB9A7763-5559-4DDE-BBAA-DAC91D876601Q33667585-EAFC75F7-948D-41C6-9865-6B86675DF2D8Q33880518-53831979-2AB2-498B-B559-D978EE2DF090Q34737498-8B580576-9917-410E-9C65-011C2CB55CACQ35054434-35B2D9D4-3438-4D48-86D0-C68E7ADBBDCAQ35110090-F3CCF69E-FACC-43DC-94AA-2933686A1286Q35679653-E4FBCB47-5216-4D5B-AAE0-02E5DDE5D4BEQ36018889-EBFAA893-2E00-483D-9C59-2FAE90F1E9A6Q37124182-26F809D3-E977-49D3-8FD1-3BC9A77F94EBQ37197347-1D0C2515-0BE4-4421-8382-0F859D41E2C5Q37358728-AB21635B-4766-42DF-AB39-9AEACA89A652Q37490618-4AD9900C-7370-424B-BDEB-40A62DEEA574Q38062949-85E27C8B-806C-4365-A6D8-FDAD1AECB09AQ38116964-7B323F0F-004B-4EEF-8C3F-81485488878DQ38199565-C2B62698-FE13-4DB2-92B5-28BB1F079270Q38202682-DDA31542-364B-41F5-AB9D-D71F9296C902Q38220594-6E40818B-15AB-4FA8-9D9E-9774452292E3Q38270848-06C6885D-F561-49A0-ABD2-404F2EB5CA20Q38620631-2C452C3E-7832-45B1-9CFC-E141C77B6A70Q38682970-4DAAD4C0-022C-47DC-9200-42CF22A886AFQ38935501-4E43BB29-C5F8-4962-A203-28079E138DEFQ39047549-FC6FFD4F-4265-4A02-B540-4ACA5DA7C41BQ39122391-AC9E505F-4FEC-4214-B567-ABAE8A960896Q39354426-7C617186-33EE-4AB0-89EC-5AA28B892B76Q40242017-E04AFBA6-D777-487B-9B8E-B913A587E0CCQ40256681-0DA10334-3FA0-412B-9CC1-454B0D5B798FQ40267497-FCC3E84B-9F87-4DCA-8447-011560A2FCB0Q40577292-D406DC0E-81E6-4082-B53F-8D06AEAD64ACQ41675994-6CBD0616-5E3B-4A46-8B03-3E67AD0A7549Q41683037-5BE9EF70-159A-4C07-A413-3D4647FDCA4BQ42217746-3D6C5C79-6BD7-49E3-A880-75C50BB93CC7Q42623959-750FEB98-7EAC-4739-9CBC-C5829D8E34F9Q43647623-A051EBD1-8DA4-4D77-95F7-5F177703F483Q44239236-4AA1EC14-03DD-4D3F-873E-9E8174B8764AQ44612152-3D5D3FED-0C96-45F9-A925-F3B56EF3A3D4Q45089736-739462B9-1A44-4503-91D3-46AD63F80208Q48001599-AB5F1679-41DC-4D13-964E-AA729E14E5D0Q48439218-5EEF8D09-AA21-4482-91A8-A3EB50E9A9E9Q51471135-100F3FC8-8342-47A2-AD24-333AC6B67D9BQ57746129-0F78649E-4B96-412E-9B79-53883F28C225
P50
description
researcher, ORCID id # 0000-0002-5022-9060
@en
wetenschapper
@nl
name
David C-M Kong
@ast
David C-M Kong
@en
David C-M Kong
@es
David C-M Kong
@nl
type
label
David C-M Kong
@ast
David C-M Kong
@en
David C-M Kong
@es
David C-M Kong
@nl
prefLabel
David C-M Kong
@ast
David C-M Kong
@en
David C-M Kong
@es
David C-M Kong
@nl
P106
P1153
7202350808
P21
P31
P496
0000-0002-5022-9060